Original Article

Comparisons of L-cysteine and D-cysteine toxicity in 4-week repeated-dose toxicity studies of rats receiving daily oral administration

Yusuke Shibui*, Ryosei Sakai†, Yasuhiro Manabe†, and Takeshi Masuyama†

1 Safety Evaluation Research Group, Fundamental Technology Labs., Institute for Innovation, Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681, Japan

Abstract: Two 4-week repeated-dose toxicity studies were conducted to evaluate the potential toxicity of L-cysteine and D-cysteine. In one study, three groups of 6 male rats were each administered L-cysteine once daily by gavage at doses of 500, 1,000, or 2,000 mg/kg/day for 28 consecutive days. The control group was administered a 0.5% methylcellulose vehicle solution. The other study followed a similar protocol except that the experimental groups received D-cysteine. Toxicological observations showed that the L-cysteine-treated groups exhibited renal injuries such as basophilic tubules with eosinophilic material in the lumen, and there were increased numbers of basophilic tubules in all treated groups. In 1,000 or 2,000 mg/kg/day-treated groups, salivation and necropsy findings indicative of focal erosion in the stomach mucosa were found. Increases in reticulocyte counts were observed in the 2,000 mg/kg/day-treated group. Toxicological findings obtained for the D-cysteine-treated groups included anemia and renal injuries such as basophilic tubules with eosinophilic material in the lumen, increased numbers of basophilic tubules, and crystal deposition in the medulla in the 2,000 mg/kg/day-treated group. Additional findings included sperm granuloma in the epididymis, necropsy findings suggestive of focal erosion in the stomach mucosa, and salivation in the 1,000 or 2,000 mg/kg/day-treated groups. One rat in the 2,000 mg/kg/day-treated group died due to renal failure. In conclusion, the no-observe-adverse-effect levels (NOAELs) were estimated to be less than 500 mg/kg/day for L-cysteine and 500 mg/kg/day for D-cysteine under our study conditions. The toxicological profiles were similar for L-cysteine and D-cysteine; however, there were slight differences in the dose responses. The mechanisms underlying these differences remain to be determined. (DOI: 10.1293/tox.2017-0002; J Toxicol Pathol 2017; 30: 217–229)

Key words: L-cysteine, D-cysteine, amino acid, toxicity, rat

Introduction

L-Cysteine, one of the amino acids that have sulfur in their chemical structures, is synthesized in the human body from L-methionine and L-serine. L-Cysteine is a nonessential amino acid in adults. However, it is considered a semi-essential amino acid in infants because they synthesize insufficient amounts; thus, L-cysteine can be lacking in this age group. The Joint FAO/WHO/UNU Expert Consultation recommends 4.1 mg/kg/day as the daily requirement of L-cysteine for healthy adults1.

L-Cysteine is a macronutrient, and it is normally found in proteins. According to a safety assessment of its use in food, there is no concern regarding the use of L-cysteine as a flavoring agent because exposure to L-cysteine through food intake is expected to be much greater than that through its use as a flavoring agent. Therefore, L-cysteine has been approved as a flavoring agent by the Joint FAO/WHO Expert Committee on Food Additives (JECFA). L-Cysteine is also considered “generally recognized as safe” (GRAS) by the Flavor and Extract Manufacturers Association (FEMA) as a flavor ingredient (FEMA No. 3263), and it is approved by the U.S. Food and Drug Administration (FDA) as a nutrient and dough strengthener, with usage limitations4, 5. L-Cysteine monohydrochloride is included in the list of designated additives in Japan by the Ministry of Health, Labour and Welfare, and it is used as an antioxidant in natural juice and as a food manufacturing agent in bread6.

D-Cysteine, the other optical isomer of cysteine, is currently not used as a food additive or flavoring agent. However, because L-cysteine is susceptible to racemization when treated with heat and under alkaline conditions, it can be assumed that substantial amounts of D-cysteine exist in processed foods7, 8.

A previous 4-week intravenous repeated-dose toxicity study of L-cysteine performed with male rats reported suppressed body weight gain, slight anemia, and histopatho-
logical findings in the cerebellum, kidney, and epididymis following l-cysteine administration. Only one study regarding l-cysteine oral toxicity has been conducted. The study was a 108-week drinking-water carcinogenicity study of l-cysteine hydrochloride in rats. It reported that l-cysteine monohydrochloride did not induce any neoplasms when administered orally to rats, but it did induce nonneoplastic lesions indicative of renal papillary necrosis. Thus, the toxicity of l-cysteine after oral administration has not been fully elucidated. By contrast, there is no information about the toxicity of d-cysteine. It has been reported that l-cysteine cannot be replaced by d-cysteine nutritionally and that replacement of l-cysteine with d-cysteine in food causes growth depression in mice under certain test conditions.

Recently, the International Council of Amino Acids Science (ICAAS) stated that insufficient safety information was available for some amino acids and that further toxicity studies are needed. Consequently, novel toxicity studies of glycine, l-phenylalanine, l-tyrosine, l-alanine, l-threonine, and l-methionine were published. As part of the safety evaluation of cysteine, we report the results of two 4-week repeated-dose oral toxicity studies in male rats administered l-cysteine or d-cysteine.

Materials and Methods

Study designs

Two 4-week repeated-dose oral toxicity studies in rats were conducted: one on l-cysteine and one on d-cysteine. We consulted the Guidelines for Toxicity Studies of Drugs for both study designs, although we did not completely follow the guidelines with respect to sex ratio, animal numbers, and organs tested in histopathology.

Animals and animal husbandry

Male CrI:CD(SD)IGS rats were obtained from Charles River Laboratories Japan (Yokohama, Japan) and allowed free access to tap water and a certified rodent diet sterilized by gamma irradiation (CRF-1, Oriental Yeast Co., Ltd., Tokyo, Japan). The contents of l-cysteine and d-cysteine derived from feed protein were not determinable because cysteine in the feed was converted to cystine in the analysis process. The cystine content of the feed protein was 0.34 g per 100 g of rodent diet, as reported by the manufacturer. The animals were housed individually in suspended, stainless steel cages in an animal room under the following conditions: temperature of 20 to 26°C, relative humidity of 30 to 70%, air ventilation 10 to 15 times/hour (all-fresh ventilation), and illumination for 12 hours per day (from 7 a.m. to 7 p.m.). The rats were acclimatized for 6 days prior to random allocation. At the initiation of treatment, the animals were 6 weeks old and weighed 207 to 227 g. All animals were treated humanely according to institutional guidelines, and the experimental procedure was approved by the institutional ethics committee.

Test articles

l-Cysteine (CAS 52-90-4, lots 105XW24 and 105XW29) supplied by Ajinomoto Co., Inc. (Kawasaki, Japan) and d-cysteine (lot 13033/1) supplied by BIOSYNTH AG (Switzerland) were stored at room temperature under light-shielded conditions. Water for injection (lots 2199, IG94, and 2F74, Otsuka Pharmaceutical Factory Inc., Tokushima, Japan) and methylcellulose (lot M8G3001, Nacalai Tesque, Inc., Tokyo, Japan) were used to prepare the vehicles for l-cysteine and d-cysteine.

Dosage preparation

For the vehicle control, 0.5% methylcellulose solution was prepared with water for injection. l-Cysteine and d-cysteine at 50, 100, or 200 mg/mL were formulated using the vehicle. l-Cysteine and d-cysteine are soluble at 50 and 100 mg/mL but not at 200 mg/mL; therefore, we prepared l-cysteine and d-cysteine in solutions at 50 and 100 mg/mL and in suspensions at 200 mg/mL.

Group designation and treatment

Animals were assigned to treatment groups according to a randomized complete block design with body weight stratification performed using a toxicological data processing system (MiTOX, Mitsui Zosen Systems Research Inc., Chiba, Japan). Each animal in the three treatment groups (6 males per group) was administered l-cysteine once daily by gavage at doses of 500, 1,000, or 2,000 mg/kg/day in a dose volume of 10 mL/kg for 28 consecutive days. Another group of 6 rats was administered the vehicle alone; this group served as the negative control group for l-cysteine treatment. For the study of d-cysteine, the same dosage groups were used as for the l-cysteine study.

Clinical observations

The animals were observed twice daily (before and after dosing) for clinical signs, including appearance/posture, behavior, feces/urine, body surface, fluid secretion/excretion, and body temperature. Individual body weight data were recorded on Days 1, 3, 7, 10, 14, 17, 21, 24, and 28, with the first day of administration defined as Day 1. Individual food and water consumption were measured on Days 7, 14, 21, and 28.

Clinical pathology

Urine samples were collected from each animal on Day 28 for approximately 18 hours and examined for pH, glucose, protein, occult blood, ketones, bilirubin, and urobilinogen using Multitix urine analysis (Siemens Healthcare Diagnostics K.K., Tokyo, Japan). Urinary volume (U. Vol) was measured, and specific gravity was determined by employing a Digital Urine Specific Gravity Refractometer (UG-D, Atago Co., Ltd., Tokyo, Japan). The urine samples were also analyzed via an electrolyte analyzer (EA06T, A&G Corporation, Tokyo, Japan) to determine the sodium ion (Na), potassium ion (K), and chloride ion (Cl) contents. Hematological and clinical chemistry parameters were evaluated on
the day of the scheduled necropsy. The animals were fasted overnight and then anesthetized with ether before blood was collected from the caudal vena cava. Blood samples containing potassium EDTA as the anticoagulant were analyzed with a total hematology system (THMS H1E, Bayer Sankyo Co. Ltd., Tokyo, Japan) to determine the red blood cell count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet count, and white blood cell count. The white blood cell differential count included neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Reticulocyte counts (per 1,000 red cells) were measured using an automated blood cell differential counter (Model 8200, Hitachi Ltd., Tokyo, Japan) in the study of L-cysteine and an automated reticulocyte counter (Sysmex CA-5000, Sysmex Corporation, Kobe, Japan) in the study of D-cysteine. The blood samples that had sodium citrate as the anticoagulant were processed with a fully automated blood coagulation analyzer (Sysmex CA-5000, Sysmex Corporation, Kobe, Japan) to determine prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen. Heparin-anticoagulated plasma samples were evaluated with an automated clinical chemistry analyzer (TBA-120FR, Toshiba Medical Systems, Inc., Tokyo, Japan) to determine lactate dehydrogenase (LDH), creatine phosphokinase (CPK), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, creatinine, blood urea nitrogen (BUN), triglycerides, total cholesterol, phospholipids, glucose, Na, K, Cl, Ca, inorganic phosphorus, and total protein. Protein fractionation, including the albumin/globulin ratio, albumin, α1 globulin, α2 globulin, β globulin, and γ globulin, was measured using an automated electrophoresis system (Rapid ElectroPhoresis, Helena Laboratories, Beaumont, TX, USA).

Postmortem evaluation

On Day 29, all surviving animals were euthanized after an overnight fast by exsanguination from the caudal vena cava under ether anesthesia. They were then subjected to complete gross pathological examination, including the external appearance of the carcass in addition to organs and tissues in the abdominal, thoracic, and cranial cavities. Although the use of ether as an anesthetic in research animals is now strongly discouraged, the experiment in this study was carried out in a manner that minimizes the use of ether. The animals that died were not obtained. Group variances for the appropriate parameters were compared using Bartlett’s method (significant at p<0.01 in two-tailed tests)9. Where group variances did not significantly differ, Dunnett’s multiple comparison method was applied to determine the significance of differences between the control group and each L-cysteine- or D-cysteine-treated group (significant at p<0.05 in two-tailed tests)20. If the Bartlett’s test indicated significant differences among group variances for a given parameter, that parameter was compared among groups using the Steel’s multiple comparison method for mean ranking (significant at p<0.05 in two-tailed tests)21.

Results

Clinical observations

Transient salivation was sporadically observed post administration in rats that received 1,000 or 2,000 mg/kg/day in the L-cysteine-treated groups and in all D-cysteine-treated groups. No significant differences in body weight were recorded between the L-cysteine-treated rats and the controls, whereas body weight was significantly lower in the 2,000 mg/kg/day D-cysteine-treated group on Day 3 than in the control group. In addition, a tendency toward suppression of body weight increase was noted in the 1,000 or 2,000 mg/kg/day D-cysteine-treated group after Day 3 (Table 1). No significant difference in food consumption was observed between the L-cysteine or D-cysteine groups and their corresponding control groups (Table 2). Water intake was significantly greater in both the L-cysteine- and D-cysteine-treated groups administered doses of 2,000 mg/kg/day than in the respective control groups. In addition, a tendency toward increased water intake was noted in the L-cysteine-treated groups receiving 500 or 1,000 mg/kg/day and in the D-cysteine group receiving 1,000 mg/kg/day (Table 3). One rat in the L-cysteine group receiving 2,000 mg/
Comparisons of $\alpha$- and $\delta$-cysteine Toxicity in Rats

Based on the results of necropsy and histopathological examination, this death was considered to be caused by accidental swallowing aspiration due to a technical error. Furthermore, a rat in the $\delta$-cysteine group receiving 2,000 mg/kg/day exhibited decreased movement and soiled fur in the perioral region on Day 18, and it died on Day 19. As described later, the results of histopathological examination suggested that this death was due to renal failure.

**Clinical pathology**

In the urinalysis, a decreasing trend was recorded for urine pH in all $\alpha$-cysteine- and $\delta$-cysteine-treated groups (Table 4). Significant increases or increasing trends were noted for urinary volume in all $\alpha$-cysteine treated groups and in the $\delta$-cysteine-treated groups receiving 1,000 or 2,000 mg/kg/day. Significant decreases or decreasing trends were noted for specific gravity in rats receiving 2,000 mg/kg/day $\alpha$-cysteine and 1,000 or 2,000 mg/kg/day $\delta$-cysteine. Occult blood was observed in the urine in the $\delta$-cysteine group administered 2,000 mg/kg/day. Regarding electrolyte excretion, significant increases in Cl excretion were noted in all $\alpha$-cysteine-treated groups and in rats receiving 1,000 or 2,000 mg/kg/day in the $\delta$-cysteine-treated groups. Na and K excretion increased significantly in the rats receiving 2,000 mg/kg/day in the $\alpha$-cysteine-treated group, whereas decreased K was noted in the rats receiving 1,000 or 2,000 mg/kg/day in the $\delta$-cysteine-treated groups. The decreased K excretion in the $\alpha$-cysteine-treated groups administered 500 or 1,000 mg/kg/day and decreased Na excretion in the $\delta$-cysteine-treated group administered 500 mg/kg/day were considered incidental owing to the lack of a dose response.

**Clinical pathology**

In the hematology analyses, significant decreases in MCV and MCH were observed in the rats receiving 1,000

### Table 1. Summary of Body Weights (g)

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>$\alpha$-cysteine</th>
<th>$\delta$-cysteine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 (Control)</td>
<td>500</td>
</tr>
<tr>
<td>Number of rats</td>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

| Day       | 213 ± 4.3 | 212 ± 3.9 | 212 ± 5.1 | 211 ± 4.5 | 218 ± 7.6 | 217 ± 5.7 | 217 ± 5.6 | 220 ± 6.4 |
| Day       | 228 ± 5.3 | 228 ± 6.2 | 227 ± 4.3 | 221 ± 13.9|
| Day       | 260 ± 5.9 | 263 ± 11.8 | 260 ± 5.0 | 261 ± 7.1  | 266 ± 12.2 | 270 ± 12.0 | 257 ± 10.0 | 255 ± 12.3 |
| Day       | 285 ± 8.0 | 286 ± 16.0 | 284 ± 5.8 | 281 ± 15.2 | 287 ± 18.0 | 294 ± 14.7 | 295 ± 14.7 | 295 ± 24.4 |
| Day       | 308 ± 6.1 | 311 ± 16.7 | 307 ± 5.6 | 305 ± 17.0 | 313 ± 26.2 | 321 ± 18.4 | 295 ± 14.7 | 295 ± 24.4 |
| Day       | 322 ± 6.4 | 329 ± 18.9 | 322 ± 6.4 | 318 ± 22.1 | 331 ± 32.2 | 339 ± 20.4 | 312 ± 24.0 |             |
| Day       | 338 ± 6.7 | 350 ± 19.6 | 338 ± 6.8 | 333 ± 26.4 | 354 ± 38.4 | 361 ± 25.1 | 327 ± 18.9 | 339 ± 6.7  |
| Day       | 351 ± 9.8 | 367 ± 20.9 | 353 ± 8.2 | 348 ± 28.1 | 370 ± 44.0 | 377 ± 27.9 | 339 ± 22.0 | 349 ± 7.5  |
| Day       | 367 ± 12.1| 384 ± 23.0 | 367 ± 9.5 | 362 ± 32.9 | 391 ± 52.9 | 396 ± 32.1 | 352 ± 23.0 | 361 ± 12.9 |

Values are means ± SD. Significantly different from the control using Dunnett’s test (two-tailed) or Steel’s test (two-tailed): *p<0.05. ^One rat died on Day 6. ^One rat died on Day 18.

### Table 2. Summary of Food Consumption (g/day)

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>$\alpha$-cysteine</th>
<th>$\delta$-cysteine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 (Control)</td>
<td>500</td>
</tr>
<tr>
<td>Number of rats</td>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

| Day       | 24.5 ± 1.2 | 25.5 ± 2.1 | 24.9 ± 0.7 | 26.1 ± 1.3 | 23.7 ± 2.6 | 24.4 ± 2.1 | 22.7 ± 1.7 | 23.9 ± 2.7 |
| Day       | 250 ± 1.8  | 268.8 ± 2.1 | 253 ± 1.2 | 250 ± 1.6  | 265 ± 4.6  | 276.6 ± 2.9 | 292 ± 7.3  | 290 ± 17.2 |
| Day       | 240 ± 1.8  | 261.2 ± 2.5 | 249 ± 0.9 | 231 ± 4.0  | 241 ± 3.9  | 240 ± 2.1  | 240 ± 2.5  | 255 ± 5.6  |
| Day       | 240 ± 1.8  | 258 ± 4.1  | 249 ± 1.6 | 254 ± 1.4  | 251 ± 4.8  | 244 ± 2.7  | 239 ± 3.5  | 243 ± 4.3  |

Values are means ± SD. ^One rat died on Day 6. ^One rat died on Day 18.

### Table 3. Summary of Water Intake (g/day)

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>$\alpha$-cysteine</th>
<th>$\delta$-cysteine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 (Control)</td>
<td>500</td>
</tr>
<tr>
<td>Number of rats</td>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

| Day       | 36.2 ± 4.4 | 39.2 ± 3.9 | 38.4 ± 3.8 | 43.8 ± 2.5* | 33.3 ± 1.4 | 34.9 ± 3.3 | 38.8 ± 3.3 | 44.2 ± 6.9** |
| Day       | 37.4 ± 4.1 | 40.4 ± 6.0 | 42.2 ± 2.7 | 46.2 ± 4.4*  | 36.3 ± 2.9  | 37.1 ± 3.3 | 38.0 ± 3.3 | 58.7 ± 20.0** |
| Day       | 36.5 ± 5.3 | 41.2 ± 7.0 | 41.0 ± 3.9 | 47.2 ± 7.2*  | 36.5 ± 6.7  | 35.5 ± 4.8 | 40.7 ± 4.6 | 51.1 ± 16.9** |
| Day       | 34.8 ± 3.1 | 40.1 ± 5.6 | 38.6 ± 3.5 | 49.1 ± 8.4** | 36.8 ± 5.9  | 36.9 ± 5.3 | 45.3 ± 7.2 | 48.7 ± 10.7** |

Values are means ± SD. Significantly different from the control using Dunnett’s test (two-tailed) or Steel’s test (two-tailed): *p<0.05; **p<0.01. ^One rat died on Day 6. ^One rat died on Day 18.
or 2,000 mg/kg/day in the d-cysteine-treated groups (Table 5). Significant decreases in hemoglobin and hematocrit and an increase in reticulocyte counts were observed in the d-cysteine-treated group receiving 2,000 mg/kg/day. Significant increases in reticulocyte count were observed in the l-cysteine-treated group receiving 2,000 mg/kg/day. Decreases or decreasing trends in PT and APTT were observed in all l-cysteine-treated groups. The increased red blood cell count observed in rats receiving 1,000 mg/kg/day in the d-cysteine-treated group was considered incidental owing to the lack of a dose response.

Regarding blood chemistry, increases in glucose were significant in the l-cysteine-treated groups receiving 1,000 or 2,000 mg/kg/day (Table 6). Increases in CPK and decreases in AST and K were significant in the l-cysteine-treated group administered 2,000 mg/kg/day. Increases in total bilirubin and decreases in ALP and BUN were significant in the d-cysteine-treated group receiving 2,000 mg/kg/day.

### Table 4. Summary of Urinalysis

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>l-cysteine</th>
<th>d-cysteine</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (Control)</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>500</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>1,000</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>2,000</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>pH</td>
<td>6.0</td>
<td>6.0</td>
</tr>
<tr>
<td>6.5</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>7.0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Glucose</td>
<td>−6</td>
<td>−6</td>
</tr>
<tr>
<td>Protein</td>
<td>−2, ±4</td>
<td>−2, ±4</td>
</tr>
<tr>
<td>Occult blood</td>
<td>−6</td>
<td>−6</td>
</tr>
<tr>
<td>Ketones</td>
<td>±4, +2</td>
<td>±4, +2</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>−6</td>
<td>−6</td>
</tr>
<tr>
<td>Urobilinogen</td>
<td>±6</td>
<td>±6</td>
</tr>
<tr>
<td>U. Vol (mL/day)</td>
<td>19.7 ± 9.6</td>
<td>25.3 ± 15.1</td>
</tr>
<tr>
<td>Specific gravity</td>
<td>1.020 ± 0.009</td>
<td>1.019 ± 0.009</td>
</tr>
<tr>
<td>Na (mEq/day)</td>
<td>0.33 ± 0.15</td>
<td>0.25 ± 0.09</td>
</tr>
<tr>
<td>K (mEq/day)</td>
<td>1.48 ± 0.13</td>
<td>1.15 ± 0.19**</td>
</tr>
</tbody>
</table>
| Values are means ± SD. Significantly different from the control using Dunnett’s test (two-tailed) or Steel’s test (two-tailed): *p < 0.05; **p < 0.01. U. Vol, urinary volume.

### Table 5. Summary of Hematology

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>l-cysteine</th>
<th>d-cysteine</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (Control)</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>500</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>1,000</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>2,000</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>RBC (10^6/μL)</td>
<td>7.85 ± 0.17</td>
<td>7.80 ± 0.49</td>
</tr>
<tr>
<td>HGB (g/dL)</td>
<td>54.1 ± 11</td>
<td>54.4 ± 2.6</td>
</tr>
<tr>
<td>MCV (fL)</td>
<td>54.1 ± 11</td>
<td>54.4 ± 2.6</td>
</tr>
<tr>
<td>MCH (pg)</td>
<td>19.4 ± 0.6</td>
<td>19.3 ± 0.9</td>
</tr>
<tr>
<td>MCHC (g/dL)</td>
<td>35.8 ± 0.6</td>
<td>35.6 ± 0.6</td>
</tr>
<tr>
<td>RET (‰)</td>
<td>30.5 ± 3.5</td>
<td>37.0 ± 7.2</td>
</tr>
<tr>
<td>PLT (10^3/μL)</td>
<td>1,056 ± 64</td>
<td>1,095 ± 56</td>
</tr>
<tr>
<td>WBC (10^3/μL)</td>
<td>8.61 ± 3.71</td>
<td>6.89 ± 1.71</td>
</tr>
<tr>
<td>BASO (10^3/μL)</td>
<td>0.05 ± 0.03</td>
<td>0.05 ± 0.03</td>
</tr>
<tr>
<td>Values are means ± SD. Significantly different from the control using Dunnett’s test (two-tailed) or Steel’s test (two-tailed): *p &lt; 0.05; **p &lt; 0.01. RBC, red blood cell count; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RET, reticulocytes; PLT, platelets; WBC, white blood cells; NEUT, neutrophils; LYM, lymphocytes; MONO, monocytes; EOS, eosinophils; BASO, basophils; PT, prothrombin time; APTT, activated partial thromboplastin time; Fbg, fibrinogen.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pathology

Increases in kidney weights (absolute weights or relative weights) were recorded in the rats receiving 1,000 or 2,000 mg/kg/day of l-cysteine in the rats receiving 1,000 or 2,000 mg/kg/day of d-cysteine (Table 7 and 8). Increases in relative liver weight were observed in rats receiving 1,000 or 2,000 mg/kg/day in the t-cysteine study and in rats receiving 2,000 mg/kg/day in the n-cysteine study,
and increases in the relative weights of both the adrenals and testes were noted in the rats receiving 2,000 mg/kg/day of l-cysteine. Decreasing trends were observed for thymus weights in the rats receiving 2,000 mg/kg/day of l-cysteine and in all d-cysteine-treated groups. Decreasing tendencies were recorded for spleen weights in rats receiving 2,000 mg/kg/day of l-cysteine.

Treatment-related gross findings were observed in the stomach in the l-cysteine- and d-cysteine-treated groups. Dark red areas of the mucosa in the glandular stomach or around the limiting ridge of the stomach were observed in 1/6 and 5/5 rats receiving 1,000 or 2,000 mg/kg/day of l-cysteine, respectively. A brown focus and brown lines were observed in the glandular stomach mucosa in 1/6 and 1/5 rats receiving 1,000 or 2,000 mg/kg/day of d-cysteine, respectively. Treatment-related gross findings were also observed in the kidney, urinary bladder, and epididymis in the d-cysteine-treated groups. Enlargement of the kidneys was observed in 3/6 and 5/5 rats receiving 1,000 or 2,000 mg/kg/day of d-cysteine, respectively. White lines in the renal papilla and scattered cysts were also observed in the kidneys in 1/5 rats receiving 2,000 mg/kg/day of d-cysteine. A distended urinary bladder with urine retention was observed in 1/5 rats receiving 2,000 mg/kg/day of d-cysteine. White nodules and enlargement of the epididymides were observed in 2/6 and 1/5 rats receiving 1,000 or 2,000 mg/kg/day of d-cysteine, respectively. Other gross findings observed in the treated groups were considered spontaneous or incidental based on the incidence or properties.

The following test article-related histopathological findings were observed in the l-cysteine-treated groups and d-cysteine-treated groups (Table 9).

Kidney: Basophilic tubules with eosinophilic material in the lumen (Fig. 1) were observed in all l-cysteine-treated groups and increases in the relative weights of both the adrenals and testes were noted in the rats receiving 2,000 mg/kg/day of l-cysteine. Decreasing trends were observed for thymus weights in the rats receiving 2,000 mg/kg/day of l-cysteine and in all d-cysteine-treated groups. Decreasing tendencies were recorded for spleen weights in rats receiving 2,000 mg/kg/day of l-cysteine.

Table 8. Summary of Relative Organ Weights

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>0 (Control)</th>
<th>500</th>
<th>1,000</th>
<th>2,000</th>
<th>0 (Control)</th>
<th>500</th>
<th>1,000</th>
<th>2,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of rats</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>5</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Body weight *(g)</td>
<td>343 ± 12</td>
<td>360 ± 22</td>
<td>340 ± 8</td>
<td>327 ± 29</td>
<td>361 ± 48</td>
<td>371 ± 29</td>
<td>326 ± 23</td>
<td>326 ± 8</td>
</tr>
<tr>
<td>Brain (mg/100g)</td>
<td>566 ± 31</td>
<td>540 ± 37</td>
<td>569 ± 24</td>
<td>595 ± 47</td>
<td>540 ± 49</td>
<td>541 ± 55</td>
<td>590 ± 59</td>
<td>603 ± 18</td>
</tr>
<tr>
<td>Thymus (mg/100g)</td>
<td>130 ± 24</td>
<td>124 ± 26</td>
<td>125 ± 12</td>
<td>101 ± 17</td>
<td>150 ± 31</td>
<td>126 ± 24</td>
<td>120 ± 30</td>
<td>120 ± 34</td>
</tr>
<tr>
<td>Heart (mg/100g)</td>
<td>363 ± 30</td>
<td>350 ± 34</td>
<td>353 ± 9</td>
<td>379 ± 28</td>
<td>343 ± 28</td>
<td>344 ± 12</td>
<td>345 ± 23</td>
<td>367 ± 33</td>
</tr>
<tr>
<td>Lung (mg/100g)</td>
<td>377 ± 22</td>
<td>382 ± 24</td>
<td>397 ± 27</td>
<td>397 ± 13</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Liver (g/100g)</td>
<td>2.71 ± 0.14</td>
<td>2.77 ± 0.13</td>
<td>2.97 ± 0.12*</td>
<td>3.07 ± 0.21**</td>
<td>2.93 ± 0.12</td>
<td>2.86 ± 0.11</td>
<td>3.01 ± 0.11</td>
<td>3.46 ± 0.16**</td>
</tr>
<tr>
<td>Spleen (mg/100g)</td>
<td>173 ± 13</td>
<td>171 ± 18</td>
<td>175 ± 32</td>
<td>151 ± 9</td>
<td>179 ± 22</td>
<td>189 ± 26</td>
<td>187 ± 19</td>
<td>216 ± 34</td>
</tr>
<tr>
<td>Kidney-R (mg/100g)</td>
<td>374 ± 27</td>
<td>368 ± 19</td>
<td>436 ± 54*</td>
<td>475 ± 21**</td>
<td>373 ± 16</td>
<td>391 ± 21</td>
<td>440 ± 34**</td>
<td>578 ± 51**</td>
</tr>
<tr>
<td>Kidney-L (mg/100g)</td>
<td>371 ± 21</td>
<td>362 ± 23</td>
<td>414 ± 43*</td>
<td>477 ± 13**</td>
<td>364 ± 20</td>
<td>391 ± 20</td>
<td>434 ± 32**</td>
<td>563 ± 44**</td>
</tr>
<tr>
<td>Adrenal-R (mg/100g)</td>
<td>7.45 ± 1.38</td>
<td>7.32 ± 0.66</td>
<td>7.94 ± 0.53</td>
<td>9.02 ± 1.09*</td>
<td>8.20 ± 0.94</td>
<td>7.94 ± 0.94</td>
<td>8.62 ± 1.16</td>
<td>9.75 ± 1.09</td>
</tr>
<tr>
<td>Adrenal-L (mg/100g)</td>
<td>7.87 ± 1.08</td>
<td>8.20 ± 0.50</td>
<td>8.09 ± 0.59</td>
<td>9.19 ± 0.77*</td>
<td>8.75 ± 1.02</td>
<td>8.22 ± 0.88</td>
<td>9.00 ± 1.49</td>
<td>10.04 ± 18</td>
</tr>
<tr>
<td>Testis-R (mg/100g)</td>
<td>459 ± 28</td>
<td>431 ± 36</td>
<td>455 ± 33</td>
<td>515 ± 34*</td>
<td>396 ± 138</td>
<td>405 ± 60</td>
<td>478 ± 71</td>
<td>481 ± 15</td>
</tr>
<tr>
<td>Testis-L (mg/100g)</td>
<td>454 ± 19</td>
<td>432 ± 35</td>
<td>449 ± 36</td>
<td>508 ± 38*</td>
<td>387 ± 134</td>
<td>416 ± 35</td>
<td>481 ± 71</td>
<td>432 ± 125</td>
</tr>
<tr>
<td>Epididymis-R (mg/100g)</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>109 ± 28</td>
<td>110 ± 11</td>
<td>121 ± 13</td>
<td>112 ± 12</td>
</tr>
<tr>
<td>Epididymis-L (mg/100g)</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>109 ± 24</td>
<td>112 ± 10</td>
<td>119 ± 13</td>
<td>99 ± 25</td>
</tr>
</tbody>
</table>

Values are means ± SD. Significantly different from the control using Dunnett’s test (two-tailed) or Steel’s test (two-tailed): *p<0.05; **p<0.01. *Terminal body weight. NE, not examined.

Table 9. Summary of Histopathology

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>0 (Control)</th>
<th>500</th>
<th>1,000</th>
<th>2,000</th>
<th>0 (Control)</th>
<th>500</th>
<th>1,000</th>
<th>2,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of rats</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>5</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Epididymis</td>
<td>Sperm granuloma</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Kidney</td>
<td>Basophilic tubules*</td>
<td>(minimal)</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(slight)</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(moderate)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Basophilic tubules with eosinophilic material in the lumen</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Focal crystal deposition in medulla</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Hyaline casts</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Stomach</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

NE, not examined. *Basophilic tubules were evaluated and scored approximately as follows: minimal, 1–5 areas of focal basophilic tubules per slide (right and left kidneys in one slide); slight, 6–15 areas of focal basophilic tubules per slide; and moderate, 16–30 areas of focal basophilic tubules per slide.
Comparisons of l- and d-cysteine Toxicity in Rats

Figure 1. Histopathological appearances of basophilic tubules with eosinophilic material in the lumen in the kidney in rats treated with l-cysteine or d-cysteine for 4 weeks. A, Control; B, 1,000 mg/kg/day l-cysteine; C, 2,000 mg/kg/day l-cysteine; D, 2,000 mg/kg/day d-cysteine. Basophilic tubules with eosinophilic material in the lumen are shown (arrows) (>200). HE staining. Scale bars in 100 μm.

Figure 2. Histopathological appearances of crystal deposition in the renal medulla in rats treated with d-cysteine for 4 weeks. A, Control; B, 2,000 mg/kg/day. Crystal deposition is shown in the renal medulla (asterisk) (>100). HE staining. Scale bars in 200 μm.

groups and in the d-cysteine-treated group receiving 2,000 mg/kg/day. Crystal deposition was observed in the medulla (Fig. 2) in one d-cysteine-treated animal receiving 2,000 mg/kg/day. Increased numbers of animals exhibited basophilic tubules in all l-cysteine-treated groups and in the d-cysteine-treated group receiving 2,000 mg/kg/day compared with the numbers in the corresponding control groups. In addition, hyaline casts were observed in rats receiving 2,000 mg/kg/day in both the l-cysteine-treated and d-cysteine-treated groups.

Stomach: Focal erosion in the glandular stomach (Fig. 3) was observed in the l-cysteine group receiving 2,000 mg/kg/day. Although gross findings were observed in the glandular stomach mucosa in the 1,000 mg/kg/day l-cysteine-treated group and 1,000 or 2,000 mg/kg/day d-cysteine-treated groups, abnormalities were not confirmed.
in the histopathological examination due to the narrow area of gross lesions.

Epididymis: Sperm granuloma (Fig. 4) was observed in the d-cysteine-treated groups receiving 1,000 or 2,000 mg/kg/day. In addition, the findings for the dead animal in the d-cysteine group administered 2,000 mg/kg/day included diffuse tubular dilatation and pelvis dilatation in the kidneys. Other histopathological findings observed in the treated groups were considered spontaneous or incidental based on the incidence or properties.

Discussion

As a part of the safety evaluation of cysteine, two separate 4-week repeated-dose oral toxicity rat studies were conducted with l-cysteine and d-cysteine. Three groups of 6 Crl:CD(SD)Igs male rats were each administered l-cysteine once daily by gavage at doses of 500, 1,000, or 2,000 mg/kg/day for 28 consecutive days. The control group was similarly administered 0.5% methylcellulose vehicle solution. Similar dosage and control groups were used for l-cysteine as for d-cysteine.

Treatment-related histopathological findings were observed in the kidneys in all l-cysteine-treated groups and in the d-cysteine group receiving 2,000 mg/kg/day. The eosinophilic material in the lumen of basophilic tubules was considered to be of erythrocyte origin (red blood cell [RBC] casts) based on the reddish rods or orbicular shapes of the eosinophilic material and the occult blood in urine in the d-cysteine group administered 2,000 mg/kg/day. These findings might indicate either damage to the interstitial blood vessels and epithelial basal lamina of proximal tubules or damage to the glomeruli; however, the precise mechanism is not clear. Crystal deposition in the medulla was observed in one rat in the d-cysteine group receiving 2,000 mg/kg/day. The crystal component was inferred to be cystine based on the following considerations: cysteine is oxidized to cystine in the blood and under other normoxic conditions, a previous report has shown that urinary excretion of inorganic sulfate was increased after oral administration of d-cysteine, and high concentrations of cystine in urine cause cystine calculi. Diffuse tubular dilatation and pelvis dilatation were observed in the kidneys of the dead animal in the
Comparison of $\alpha$- and $\beta$-Cysteine Toxicity in Rats

The decreases in hemoglobin, hematocrit, MCV, and MCH, increased reticulocyte counts, and increased total bilirubin in rats receiving 2,000 mg/kg/day of $\alpha$-cysteine all suggest mild anemia. This anemic change was accompanied by the decreases in MCV and MCH, which indicate microcytic anemia. The common cause for microcytic anemia is iron deficiency. In this study, there were hemorrhagic changes at necropsy in stomachs and RBC casts in histopathology of kidneys, which might have induced prolonged hemorrhage and iron deficiency. In rats receiving 1,000 mg/kg/day of $\alpha$-cysteine, although decreases in MCV and MCH were observed, there were no changes in hemoglobin, hematocrit, and red blood cell count, and thus these changes were considered not toxicologically significant. Increased reticulocyte counts were observed in rats receiving 2,000 mg/kg/day of $\alpha$-cysteine. Given that there were hemorrhagic changes in the stomachs and RBC casts in the kidneys in the rats receiving 2,000 mg/kg/day of $\alpha$-cysteine, the increased reticulocyte counts probably indicate a compensatory change caused by potential anemia, and thus were considered toxicologically significant. In addition, anemic findings were observed in an intravenous study of $\alpha$-cysteine in rats receiving 1,000 mg/kg/day, which indicates that higher exposure to $\alpha$-cysteine induces anemia.

Slight suppression of body weight increase was recorded from Day 3 until the end of the dosing period in the $\alpha$-cysteine groups receiving 1,000 or 2,000 mg/kg/day; however, no significant suppression of body weight increase was subsequently observed after Day 3, and the body weights of the animals receiving 1,000 or 2,000 mg/kg of $\alpha$-cysteine were mostly within the range observed in the control group on Day 28 (control group, 328–474 g; 1,000 mg/kg/day $\alpha$-cysteine-treated group, 324–385 g; and 2,000 mg/kg/day $\alpha$-cysteine-treated group, 346–378 g). Thus, we considered this change to not be toxicologically significant. Previous reports have shown that oral administration of $\alpha$-cysteine at a higher dose range induced reductions of body weight gain and food intake in rats$^{31,33}$; however, in our study, such changes were not observed at doses up to 2,000 mg/kg/day.

Transient salivation post administration was observed in the $\alpha$-cysteine groups receiving 1,000 and 2,000 mg/kg/day and in all $\alpha$-cysteine-treated groups. Salivation was considered to be due to oral irritation or a CNS effect of $\alpha$- and $\beta$-cysteine because $\alpha$- and $\beta$-cysteine have a sulfurous taste$^{34}$ and salivation was observed in most of the rats receiving 1,000 mg/kg/day in a 28-day intravenous study with $\alpha$-cysteine in rats$^{5}$. There were no histopathological changes in the brain in the present study and no histopathological changes in the salivary glands in a previous intravenous study$^{5}$. In the rats receiving 500 mg/kg/day of $\alpha$-cysteine, salivation was only observed in one rat on 2 days during the administration period. We conclude that there is no toxicological significance of salivation after 500 mg/kg/day $\alpha$-cysteine administration and that there is toxicological
Table 10. Summary of Results of 4-week Oral Toxicity Studies with L-cysteine and D-cysteine in Male Rats

<table>
<thead>
<tr>
<th>Dose (mg/kg/day)</th>
<th>L-cysteine</th>
<th>D-cysteine</th>
</tr>
</thead>
<tbody>
<tr>
<td>0, 500, 1,000, 2,000</td>
<td>1,000 mg/kg/day or more: Salivation</td>
<td>1,000 mg/kg/day or more: Salivation</td>
</tr>
<tr>
<td>1,000 mg/kg/day or more: Sperm granuloma in the epididymis</td>
<td>2,000 mg/kg/day or more: One death (renal failure)</td>
<td></td>
</tr>
<tr>
<td>Body weight</td>
<td>NAD</td>
<td>NAD</td>
</tr>
<tr>
<td>Food consumption</td>
<td>NAD</td>
<td>NAD</td>
</tr>
<tr>
<td>Water intake</td>
<td>500 mg/kg/day or more: Increased</td>
<td>1,000 mg/kg/day or more: Increased</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>500 mg/kg/day or more: Increased in urinary volume and Cl excretion, and decreased in specific gravity</td>
<td>1,000 mg/kg/day or more: Increased in urinary volume and Cl excretion, and decreased in K excretion and specific gravity</td>
</tr>
<tr>
<td>Hematology</td>
<td>2,000 mg/kg/day: Increased in reticulocyte count</td>
<td>2,000 mg/kg/day: Decreased in hemoglobin, hematocrit, MCV and MCH, and increased in reticulocyte count</td>
</tr>
<tr>
<td>Clinical chemistry</td>
<td>2,000 mg/kg/day: Decreased in K</td>
<td>2,000 mg/kg/day: Increased in total bilirubin</td>
</tr>
<tr>
<td>Organ weight</td>
<td>1,000 mg/kg/day or more: Increased in the kidney</td>
<td>1,000 mg/kg/day or more: increased in the kidney</td>
</tr>
<tr>
<td>Necropsy</td>
<td>1,000 mg/kg/day or more: Dark red areas in the glandular stomach</td>
<td>1,000 mg/kg/day or more: Enlargement of the kidney, brown focus and brown lines in the glandular stomach, and white nodule and enlargement of the epididymis, and enlargement of the epididymis</td>
</tr>
<tr>
<td>2,000 mg/kg/day: Focal erosion in the glandular stomach and hyaline cast in the kidney</td>
<td>2,000 mg/kg/day: White lines in the papillary and scattered cysts in the kidney, and distended urinary bladder with urine retention</td>
<td></td>
</tr>
<tr>
<td>Histopathology</td>
<td>500 mg/kg/day or more: Basophilic tubule with eosinophilic material in the lumen and increase of basophilic tubules in the kidney</td>
<td>1,000 mg/kg/day or more: Sperm granuloma in the epididymis</td>
</tr>
<tr>
<td>2,000 mg/kg/day: Basophilic tubule with eosinophilic material in the lumen, increase of basophilic tubules, hyaline cast, and focal crystal deposition in the medulla in the kidney</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NAD: no abnormality detected.

significance of salivation after 1,000 or 2,000 mg/kg/day L-cysteine or D-cysteine administration.

Other changes in clinical pathology parameters or organ weights were not considered toxicologically significant because these changes were minimal and because no related changes were observed in the necropsy and histopathology findings or in other related parameters.

The findings that were considered toxicologically significant are summarized and compared in Table 10.

The toxicological findings were similar between L-cysteine and D-cysteine; however, there were slight differences between them in terms of the dose responses. Anemia was observed with D-cysteine treatment but not with L-cysteine treatment. However, increased reticulocyte counts, which might indicate potential anemia, were also observed in rats receiving 2,000 mg/kg/day of L-cysteine. In addition, anemia has been observed following intravenous administration of L-cysteine. By contrast, histopathological findings in the kidney were observed at the lower doses of L-cysteine but not at the lower doses of D-cysteine. It has been reported that the plasma cystine concentration is higher post D-cysteine administration than post L-cysteine administration. In addition, the metabolic pathways differ between L-cysteine and D-cysteine, and fewer enzymes are associated with D-cysteine metabolism than with L-cysteine metabolism. The differences in the dose responses in our study potentially reflect differences in the metabolism of L-cysteine and D-cysteine. However, additional toxicokinetic studies of L-cysteine and D-cysteine are needed to clarify the mechanism.

We note that although we consulted the Guidelines for Toxicity Studies of Drugs, we did not completely follow the guidelines with respect to sex ratio, the number of animals, and the organs examined in histopathology.

In conclusion, L-cysteine-related toxicological effects were observed in the kidney and stomach, and D-cysteine-related toxicological effects were observed in the kidney, epididymis, and stomach. In addition, salivation and mild anemia were observed in the D-cysteine-treated groups. Increased reticulocyte counts and salivation were observed in the L-cysteine-treated groups. Under our study conditions, the no-adverse-effect levels (NOAELs) were determined to be less than 500 mg/kg/day for L-cysteine and 500 mg/kg/day for D-cysteine. Additional toxicokinetic studies of L-cysteine and D-cysteine are needed to clarify the mechanisms underlying the differences in toxicological dose responses between L- and D-cysteine.

Disclosure of Potential Conflicts of Interest: The authors declare that there is no conflict of interest in this study.
References


3. Oser BL, and Hall RL. Recent progress in the consideration of flavoring ingredients under the food additives amendment. 5. GRAS substances. Food Technol. 26: 35–42. 1972.


dents and humans. Int J Obes. 39: 447–455. 2015. [Medline] [CrossRef]
34. Solms J. [The taste of amino acids, peptides and proteins]. Int Z Vitaminforsch. 39: 320–322. 1969. [in German] [Medline]